Kura Oncology (NASDAQ:KURA) Stock Rating Reaffirmed by JMP Securities

Kura Oncology (NASDAQ:KURAGet Free Report)‘s stock had its “market outperform” rating reiterated by analysts at JMP Securities in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $32.00 price target on the stock. JMP Securities’ target price points to a potential upside of 61.86% from the company’s current price.

A number of other equities analysts have also recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Friday, May 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of Kura Oncology in a report on Tuesday, May 14th. Finally, StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $28.36.

View Our Latest Analysis on KURA

Kura Oncology Stock Performance

Shares of KURA stock opened at $19.77 on Tuesday. The stock has a market cap of $1.51 billion, a PE ratio of -9.11 and a beta of 0.94. The business has a 50-day simple moving average of $20.54 and a 200-day simple moving average of $18.85. The company has a quick ratio of 16.67, a current ratio of 16.67 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $7.41 and a 52-week high of $24.17.

Kura Oncology (NASDAQ:KURAGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). The business’s revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.50) earnings per share. On average, equities analysts expect that Kura Oncology will post -2.56 EPS for the current year.

Insider Activity

In other news, insider Teresa Brophy Bair sold 2,615 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $22.15, for a total value of $57,922.25. Following the completion of the sale, the insider now directly owns 68,979 shares in the company, valued at $1,527,884.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. BVF Inc. IL lifted its holdings in Kura Oncology by 9.5% in the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock valued at $106,027,000 after acquiring an additional 642,245 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in Kura Oncology by 35.1% in the third quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company’s stock valued at $39,891,000 after acquiring an additional 1,136,044 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Kura Oncology by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after acquiring an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in Kura Oncology by 29.2% in the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after acquiring an additional 870,000 shares during the last quarter. Finally, Armistice Capital LLC lifted its holdings in Kura Oncology by 5.3% in the third quarter. Armistice Capital LLC now owns 2,236,000 shares of the company’s stock valued at $20,392,000 after acquiring an additional 112,000 shares during the last quarter.

About Kura Oncology

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Further Reading

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.